Ikena Oncology, Inc. IKNA
Set alert
17.16 0.00 0.00%
At close · Jul 25
1.36 Day range 17.16
1.22 52-week range 2.29
- Open
- 1.38
- Prev close
- 17.16
- Mkt cap
- 80.59M
- Vol
- 457.26K
- Avg vol
- 72.44K
- EPS
- -1.23
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.36
- High
- 17.16
- Forward P/E
- -1.96
- Beta
- 0.48
- Short ratio
- 1.23
- Inst. own
- 63.54%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 1.69
- 200-d avg
- 1.60
- 1y target
- 3.00
Analyst view
Consensus: none
Price target (mean) 3.00 -82.5% downside
Now 17.16
- Target (low)
- 2.00
- Target (mean)
- 3.00
- Target (high)
- 4.00
Ratings (0m) 3 2 buy · 1 hold · 0 sell
- Strong buy1
- Buy1
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 3
- 2 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.17 | -0.17 – -0.17 | -0.40 | +57.5% | 0 | -100.0% | 1 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Current year | -0.92 | -0.92 – -0.92 | -1.63 | +43.6% | 0 | -100.0% | 1 |
| Next year | -0.84 | -1.08 – -0.60 | -0.92 | +8.7% | 0 | 0.0% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 12, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 29, 2024 | Wedbush | Downgrade | Outperform | Neutral |
| May 29, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 14, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Mar 19, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 12, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jan 19, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Jan 19, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 9, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 22, 2023 | Wedbush | Initiated | — | Outperform |
| Aug 10, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 7, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 24, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 16, 2023 | Credit Suisse | Reiterated | Outperform | Outperform |
| Mar 17, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Mar 15, 2023 | Credit Suisse | Maintained | — | Outperform |
| Nov 29, 2022 | Credit Suisse | Maintained | — | Outperform |
| Nov 29, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Nov 8, 2022 | Credit Suisse | Maintained | — | Outperform |
| May 13, 2022 | Credit Suisse | Maintained | — | Outperform |
| Apr 13, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Dec 23, 2021 | HC Wainwright & Co. | Initiated | — | Buy |
| Aug 13, 2021 | Credit Suisse | Maintained | — | Outperform |
| Apr 20, 2021 | Jefferies | Initiated | — | Buy |
| Apr 20, 2021 | William Blair | Initiated | — | Outperform |
| Apr 20, 2021 | Credit Suisse | Initiated | — | Outperform |